Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Basal Cell

Pancreatic Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Hematopoietic and Lymphoid System Neoplasm

Breast Neoplasms

Stage I Mixed Cell Type Kidney Wilms Tumor

Pleuropulmonary blastoma

Prostatic Neoplasms

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Large B-Cell, Diffuse

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Neoplasm Metastasis

Prostatic Neoplasms

Rectal Neoplasms

Carcinoma, Oropharyngeal Neoplasms

Brain Neoplasms, Breast Neoplasms, Cardiotoxicity

Carcinoma, Basal Cell

Prostatic Neoplasms

Endometrial Neoplasms

Endometrial Neoplasms

Lymphoma, Large B-Cell, Diffuse

Esophageal Neoplasms

Colonic Neoplasms

Stomach Neoplasms

Uterine Cervical Neoplasms

Clinical Trials

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

LAP100

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Communication Issues in Patient and Provider Discussions of Immunotherapy

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

GU-01

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Senolytics

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

SABR-SYNC

DIVINE

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

RADIOSONIC

LUMEN-1

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

PROBEAT

RAINBO

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

ADAGE

Metronomic Capecitabine in Stage III Gastric Cancer

CQGOG0102